Immutep LAG-3 Inhibitor May Have Path Forward

 
• By Joseph Haas
  
3d illustration of T cells attacking a cancer cell
Immutep thinks its LAG-3 inhibitor can improve immune response for PD-1 agents
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D